ZA977868B - Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors. - Google Patents

Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors.

Info

Publication number
ZA977868B
ZA977868B ZA9707868A ZA977868A ZA977868B ZA 977868 B ZA977868 B ZA 977868B ZA 9707868 A ZA9707868 A ZA 9707868A ZA 977868 A ZA977868 A ZA 977868A ZA 977868 B ZA977868 B ZA 977868B
Authority
ZA
South Africa
Prior art keywords
protease inhibitors
making hiv
intermediates
methods
hiv
Prior art date
Application number
ZA9707868A
Other languages
English (en)
Inventor
Srinivasan Babu
Bennett C Borer
Travis P Remarchuk
Robert J Szendroi
Kathleen R Whitten
Juliette K Busse
Kim F Albizati
Original Assignee
Agouron Pharma
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Japan Tobacco Inc filed Critical Agouron Pharma
Publication of ZA977868B publication Critical patent/ZA977868B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9707868A 1996-09-05 1997-09-02 Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors. ZA977868B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/708,607 US5705647A (en) 1996-09-05 1996-09-05 Intermediates for making HIV-protease inhibitors

Publications (1)

Publication Number Publication Date
ZA977868B true ZA977868B (en) 1998-03-30

Family

ID=24846475

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9707868A ZA977868B (en) 1996-09-05 1997-09-02 Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors.

Country Status (16)

Country Link
US (1) US5705647A (zh)
EP (1) EP0931071B1 (zh)
JP (2) JP2001501183A (zh)
AR (1) AR009532A1 (zh)
AT (1) ATE397591T1 (zh)
AU (1) AU4247097A (zh)
CA (1) CA2264725A1 (zh)
CO (1) CO4900044A1 (zh)
DE (1) DE69738751D1 (zh)
ES (1) ES2306461T3 (zh)
ID (1) ID17012A (zh)
IN (1) IN183739B (zh)
MY (1) MY132553A (zh)
UY (1) UY24697A1 (zh)
WO (1) WO1998009952A1 (zh)
ZA (1) ZA977868B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6130348A (en) * 1997-04-10 2000-10-10 Hoffmann-La Roche Inc. Process for a phenylthiobutyl-isoquinoline and intermediates therefor
CA2286013C (en) * 1997-04-10 2003-07-15 F. Hoffmann-La Roche Ag Process for making a butylthio-isoquinoline and intermediates therefor
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
WO1999048371A1 (en) * 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
US20050049242A1 (en) * 2000-12-21 2005-03-03 W. Edward Robinson Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
CA2456229A1 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
SG145574A1 (en) * 2003-05-08 2008-09-29 Pfizer Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
KR101449353B1 (ko) * 2010-10-22 2014-10-08 미쓰이 가가쿠 가부시키가이샤 환상 황산 에스테르 화합물, 그것을 함유하는 비수 전해액, 및 리튬이차전지

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
CS35692A3 (en) * 1991-02-08 1992-09-16 Sankyo Co Novel beta-amino-alpha-hydroxycarboxylic acids and pharmaceuticalcompositions comprising thereof
US5235039A (en) * 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
DE4126482A1 (de) * 1991-08-10 1993-02-11 Bayer Ag (alpha)-trifluormethyl-substituierte, gesaettigt-bicyclische amine und verfahren zu deren herstellung
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
EP0534511A1 (en) * 1991-08-16 1993-03-31 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5256783A (en) * 1991-09-18 1993-10-26 Hoffmann-La Roche Inc. Method for producing 2-isoquinoline compounds
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
AU3278293A (en) * 1991-12-20 1993-07-28 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
DE69300043T2 (de) * 1992-03-13 1995-05-24 Bio Mega Boehringer Ingelheim Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer.
EP1447398A1 (en) * 1992-05-21 2004-08-18 Monsanto Company Retroviral protease inhibitors
PT810209E (pt) * 1992-08-25 2002-09-30 Searle & Co Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral
ES2103488T3 (es) * 1992-08-25 1997-09-16 Searle & Co N-(alcanoilamino-2-hidroxipropil)sulfonamidas utiles como inhibidores de proteasas retrovirales.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
WO1998009952A1 (en) 1998-03-12
ES2306461T3 (es) 2008-11-01
ATE397591T1 (de) 2008-06-15
JP2001501183A (ja) 2001-01-30
AU4247097A (en) 1998-03-26
JP2009040788A (ja) 2009-02-26
MY132553A (en) 2007-10-31
DE69738751D1 (de) 2008-07-17
UY24697A1 (es) 1997-10-21
EP0931071A1 (en) 1999-07-28
ID17012A (id) 1997-11-27
IN183739B (zh) 2000-04-01
AR009532A1 (es) 2000-04-26
CA2264725A1 (en) 1998-03-12
CO4900044A1 (es) 2000-03-27
US5705647A (en) 1998-01-06
EP0931071B1 (en) 2008-06-04

Similar Documents

Publication Publication Date Title
PL331856A1 (en) Heterocyclic inhibitors of metaloprotease
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
AP9701054A0 (en) Inhibitors of cycteine protease
ZA973146B (en) Prodrugs of COX-2 inhibitors.
HUP9800634A3 (en) P-amidino-benzylamide derivatives as thrombin inhibitors, intermediates and use thereof
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
PL331920A1 (en) Spirocyclic inhibitors of metaloproteases
PL328665A1 (en) Inhibitors of serinic protease
ZA977868B (en) Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors.
GB2346823B (en) Reamer and method of using the same
PL318452A1 (en) Method of obtaining peroxyperfluoropolyoxyalkylenes
AU2277597A (en) New inhibitors of sh2-mediated processes
PL330400A1 (en) Method of obtaining azacyclohexapeptides
HUP0004855A3 (en) Method for the synthesis of quinoline derivatives and intermediates
EP1085872A4 (en) TRANSCRIPTION FACTOR NF- $ g (k) B INHIBITORS
IL128614A0 (en) Naphthyl compounds, intermediates, compositions, and methods of use
PL333984A1 (en) Method of obtaining n-substituted 3-hydroxypyrazoles
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
PL313419A1 (en) Method of obtaining beta-naphtole
PL333977A1 (en) Method of obtaining benzisothiazolyn-3-ones
AP9901497A0 (en) Intermediates for making hiv-protease inhibitors and methods of making hiv-protease inhibitors
PL321925A1 (en) Method of obtaining 1-(p-methoxybenzooyl)-2-pyrolydone
PL332075A1 (en) Method of obtaining nizathidine
PL317788A1 (en) Method of obtaining 3-isocyanate-propylsilane
PL332208A1 (en) Method of obtaining benzzothiophenes